Cisplatin-loaded superparamagnetic nanoparticles modified with PCL-PEG copolymers as a treatment of A549 lung cancer cells

• Main Authors: Sonia Fathi Karkan, Soodabeh Davaran, Abolfazl Akbarzadeh
• Format: Article
• Language: English
• Published: Iranian Society of Nanomedicine 2019-12-01
• Series: Nanomedicine Research Journal
• Subjects: cisplatin; lung cancer; medicine delivery; pcl-peg-pcl; 〖fe〗_3 o_4 superparamagnetic nanoparticles
• Online Access: http://www.nanomedicine-rj.com/article_37796_c82595d12e7aa3596aabcbe3e6a5b189.pdf
• ISSN: 2476-3489; 2476-7123

Magnetic nanoparticles have been highly regarded because of their unique properties, such as hyperthermia, medicine control release, and diagnostic applications. The main aim of the current paper is to offer a new system for the modification of Fe3O4 (SPIONs) superparamagnetic nanoparticles physically and chemically with polymers through physical retention. These modified nanoparticles have been used to encapsulate cisplatin as an anticancer medicine and the effect of nanocapsulated cisplatin has been studied in lung cancer (A549) cell line. Using ring-opening polymerization Triblock copolymer PCL-PEG-PCL was prepared of ɛ-caprolactone (PCL) in the presence of polyethylene glycol (PEG). Magnetic iron nanoparticles were also prepared and identified. Using Fourier Transform Infrared Spectroscopy (FTIR), the bulk features of the copolymers were determined. Nanoparticles loaded with Cisplatin have been ready using the copolymer containing iron superparamagnetic nanoparticles via double emulsion solvent evaporation method and evaluated for medicine entrapment efficiency (%), the quantity of medicine, size, and surface morphology. Cytotoxic tests have been considered using the MTT assay method in lung carcinoma (A549)-treated cells. The results of the study demonstrated that nanocapsulated cisplatin had a significant cytotoxic and anticancer effect in vitro of the lung cancer cell line and it can be concluded that this approach has the ability to fail some of the main chemotherapy constraints and can be an appropriate approach for future programs in the treatment of lung cancer.